Astrazeneca plc, of London, said the FDA has accepted the BLA for durvalumab, a PD-L1 human monoclonal antibody for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed during or after one standard platinum-based regimen.